Inhibition of cell proliferation by the somatostatin analogue RC-160 is mediated by somatostatin receptor subtypes SSTR2 and SSTR5 through different mechanisms
about
Phenolic antioxidants trolox and caffeic acid modulate the oxidized LDL-induced EGF-receptor activationIdentification of multiple somatostatin receptors in the rat somatosensory cortex during developmentSomatostatin receptors 2 and 5 are preferentially expressed in proliferating endotheliumTranscriptional activation of mouse sst2 somatostatin receptor promoter by transforming growth factor-beta. Involvement of Smad4.The antiproliferative effects of somatostatin receptor subtype 2 in breast cancer cells.Expression of somatostatin, cortistatin, and somatostatin receptors in human monocytes, macrophages, and dendritic cells.Somatostatin receptor-mediated signaling in smooth muscle. Activation of phospholipase C-beta3 by Gbetagamma and inhibition of adenylyl cyclase by Galphai1 and Galphao.Somatostatin receptors in gastrointestinal stromal tumors: new prognostic biomarker and potential therapeutic strategySomatostatin analogues in the treatment of endocrine tumors of the gastrointestinal tract.Lipophilization of somatostatin analog RC-160 with long chain fatty acid improves its antiproliferative and antiangiogenic activity in vitro.Mechanism and its regulation of tumor-induced angiogenesis.Inhibition of growth and metastatic progression of pancreatic carcinoma in hamster after somatostatin receptor subtype 2 (sst2) gene expression and administration of cytotoxic somatostatin analog AN-238.SST3-selective potent peptidic somatostatin receptor antagonists.A switch of G protein-coupled receptor binding preference from phosphoinositide 3-kinase (PI3K)-p85 to filamin A negatively controls the PI3K pathway.Synthesis and biological evaluation of cytotoxic analogs of somatostatin containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin.Critical role of Src and SHP-2 in sst2 somatostatin receptor-mediated activation of SHP-1 and inhibition of cell proliferationSomatostatin receptor subtype mRNA expression in human colorectal cancer and normal colonic mucosae.Analysis of somatostatin receptor subtype mRNA expression in human breast cancer.Treatment of endocrine pancreatic tumors.Alteration of somatostatin receptor 2 expression in canine mammary gland tumor.Feasibility, endocrine and anti-tumour effects of a triple endocrine therapy with tamoxifen, a somatostatin analogue and an antiprolactin in post-menopausal metastatic breast cancer: a randomized study with long-term follow-up.Control of gastric acid secretion in somatostatin receptor 2 deficient mice: shift from endocrine/paracrine to neurocrine pathwaysSSTR2 promoter hypermethylation is associated with the risk and progression of laryngeal squamous cell carcinoma in males.Characterization of the antiproliferative signal mediated by the somatostatin receptor subtype sst5.Phase II study of RC-160 (vapreotide), an octapeptide analogue of somatostatin, in the treatment of metastatic breast cancer.Peptide receptor targeting in cancer: the somatostatin paradigm.Medical management of pancreatic neuroendocrine tumors.A tumor-selective somatostatin analog (TT-232) with strong in vitro and in vivo antitumor activity.Characterization of intracellular signaling mediated by human somatostatin receptor 5: role of the DRY motif and the third intracellular loop.Analog of somatostatin vapreotide exhibits biological effects in vitro via interaction with neurokinin-1 receptor.Identification of human somatostatin receptor 2 domains involved in internalization and signaling in QGP-1 pancreatic neuroendocrine tumor cell line.Induction of a negative autocrine loop by expression of sst2 somatostatin receptor in NIH 3T3 cells.Somatostatin and opioid receptors do not regulate proliferation or apoptosis of the human multiple myeloma U266 cells.Replication-deficient rSV40 mediate pancreatic gene transfer and long-term inhibition of tumor growth.Regulation of neuronal nitric-oxide synthase activity by somatostatin analogs following SST5 somatostatin receptor activation.Restoration of functional gap junctions through internal ribosome entry site-dependent synthesis of endogenous connexins in density-inhibited cancer cellsSomatostatin inhibits PDGF-stimulated Ras activation in human neuroblastoma cells.Induction of wild-type p53, Bax, and acidic endonuclease during somatostatin-signaled apoptosis in MCF-7 human breast cancer cells.Involvement of MAP kinase and c-fos signaling in the inhibition of cell growth by somatostatin.Induction of apoptosis in neuroendocrine tumors of the digestive system during treatment with somatostatin analogs.
P2860
Q28363066-758F3345-F527-49D5-9677-FC85A4E5C62AQ28570904-594C645A-FD90-47DF-8266-65F9623C12A5Q30486819-69FA9D24-3AC5-4E9F-AD92-F399F23FF3C1Q30984837-C03FCCA6-1FCE-49FF-B52A-0FD7F5EAB105Q33552691-E78D2C64-2B31-4AF5-9FB7-EB7618C4F76AQ34189365-3C80891B-7223-4A29-8DEA-133CB999B2DAQ34396329-758EBE1A-8CDB-4F0D-B30A-63BB40B6ED61Q34978826-5B90535D-2FC8-4832-BAF3-10FD4833B47AQ35020349-7160E8BB-1EF0-4F0F-99A3-9DEFA86999B8Q35107573-A9F62E8E-EC71-4831-AD6C-BDDACF03109BQ35151099-C086BBF7-473C-4005-8665-FA577CA58F7DQ35199203-CF0335CE-3A76-4079-89B9-DB5021473D5BQ35582980-C85B4285-A062-4893-9101-7104EF513E16Q35807246-7125F674-CC01-40FE-B50B-79876BDA38D1Q35891113-ACD77ABB-2108-474E-9A12-2A4256987F54Q35973795-459A617C-C3BD-410D-BC55-5F13D8804CC2Q36116318-DB3AEB0F-1B44-440D-AD70-C1E5707A63FBQ36116487-0C1882C8-F823-4AE2-88A9-5D4972B54889Q36239955-C989A4F9-4571-4C90-B0FA-EFA3365A241FQ36263767-7C4EAD8A-2B11-4DA6-B839-465F467BCE87Q36295053-EDB251E3-B7FF-4F03-924D-8F74D7F33DCEQ36415827-5BAF58BC-BB5C-4469-B1D4-AD8AF71C859DQ36489918-CF6C335C-1C47-4537-BB25-0D2D4190A8B6Q36566036-7FCBC80A-4FDE-4B4C-A6E1-C611621FA2B0Q36619058-F3C13CB9-289D-4564-945D-EF059D094370Q36638046-FFE595A8-8C82-40C3-8A29-D0893249DF9AQ37009032-498EDB81-6385-49BA-A8BB-AC2CF7E5CB7DQ37242234-857E7DA9-6B19-4388-9D0C-90931305301AQ37244709-6BE12675-A2EC-403C-9723-18AB7CFFA8BFQ37340453-FFB3AF11-A120-4EB3-B8BA-D8582D9C3146Q38758506-01D3A25A-9806-41CC-8B09-2E48C82A42C0Q39763546-C24D74B3-BFDD-4688-A05B-6C340988F9A0Q39842258-755527E4-6860-49DD-9FBA-BFD12C184F33Q40228737-AD2B984C-11AF-4F8D-8D23-E2C9F814566BQ40281065-020C5AD5-C143-4F2D-AFE0-B74003ECC4FFQ40427070-8229DED9-301C-4447-937B-6CE721966053Q40925307-62826F71-014E-4F25-91EF-0A64594E889DQ41051419-DBC7B106-469A-42B8-9946-18719B2CCB48Q41112864-C86B6E07-DC0A-4D49-944E-50F9E20CD777Q41136882-1106FD9B-2C56-451C-827B-7AAF676678E9
P2860
Inhibition of cell proliferation by the somatostatin analogue RC-160 is mediated by somatostatin receptor subtypes SSTR2 and SSTR5 through different mechanisms
description
1995 nî lūn-bûn
@nan
1995 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1995 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
name
Inhibition of cell proliferati ...... 5 through different mechanisms
@ast
Inhibition of cell proliferati ...... 5 through different mechanisms
@en
Inhibition of cell proliferati ...... 5 through different mechanisms
@nl
type
label
Inhibition of cell proliferati ...... 5 through different mechanisms
@ast
Inhibition of cell proliferati ...... 5 through different mechanisms
@en
Inhibition of cell proliferati ...... 5 through different mechanisms
@nl
prefLabel
Inhibition of cell proliferati ...... 5 through different mechanisms
@ast
Inhibition of cell proliferati ...... 5 through different mechanisms
@en
Inhibition of cell proliferati ...... 5 through different mechanisms
@nl
P2093
P2860
P356
P1476
Inhibition of cell proliferati ...... 5 through different mechanisms
@en
P2093
A M O'Carroll
J P Estève
N Saint-Laurent
V Bertrand
P2860
P304
P356
10.1073/PNAS.92.5.1580
P407
P577
1995-02-01T00:00:00Z